CopperLan

Background Meta analyses EBCTCG, Lancet 2005; 365 2687 have established in estrogen receptor ER positive breast cancer BC that 5 yrs of adjuvant tamoxifen Tam substantially reduces recurrence and mortality <a href=https://stromectol.autos/>stromectol pill for humans</a> Results from these experiments prove that antagonism of the ER in vitro can facilitate an increase in target protein expression on breast tumors